HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

fluchloralin

structure

Also Known As:

Basalin; N-(2-chloroethyl)-2,6-dinitro-N-propyl-4-(trifluoromethyl)aniline; N-(2-chloroethyl)-N-propyl-2,6-dinitro-4-trifluoromethylaniline

Networked: 7 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Aniline Compounds: 46
    - fluchloralin: 7

Experts

1.	Dong, Chao: 2 articles (01/2019 - 01/2018)
2.	Dong, Yanhu: 2 articles (01/2019 - 01/2018)
3.	Gao, Weiguo: 2 articles (01/2019 - 01/2018)
4.	Hu, Xia: 2 articles (01/2019 - 01/2018)
5.	Jiang, Jikang: 2 articles (01/2019 - 01/2018)
6.	Zhang, Lei: 2 articles (01/2019 - 01/2018)
7.	Ding, Bo: 1 article (01/2021)
8.	Jing, Ting: 1 article (01/2021)
9.	Li, Huiqin: 1 article (01/2021)
10.	Ma, Jianhua: 1 article (01/2021)

Related Diseases

1.	Diabetes Mellitus 01/01/2018 - "Switching from biosimilar (Basalin) to originator (Lantus) insulin glargine is effective in Chinese patients with diabetes mellitus: a retrospective chart review."
2.	Type 2 Diabetes Mellitus (MODY) 02/01/2018 - "To determine the clinical non-inferiority of recombinant glargine-Basalin vs glargine-Lantus, in treatment of type 2 diabetes mellitus (T2DM) using continuous glucose monitoring system (CGMS). " 02/01/2018 - "A comparison of clinical efficacy and economic value in Basalin- and Lantus-treated patients with type 2 diabetes using continuous glucose monitoring system." 01/01/2021 - "This study aims at evaluating glycemic control during Basalin or Lantus administration in adults with controlled type 2 diabetes mellitus using continuous glucose monitoring system (CGM). " 01/01/2021 - "Evaluating Glycemic Control During Basalin or Lantus Administration in Adults With Controlled Type 2 Diabetes Mellitus Using Continuous Glucose Monitoring."
3.	Hypoglycemia (Reactive Hypoglycemia) 01/01/2018 - "The incidence of confirmed hypoglycemia was low during Basalin (2 [2.4%]) and Lantus (1 [1.2%]) treatment, with no cases of severe hypoglycemia. " 01/01/2019 - "Hypoglycemia was infrequent in both Basalin and Lantus treatment (one vs. four patients, respectively; p = 1.00) and no severe hypoglycemic events were reported. " 01/01/2021 - "Variables of CGM, such as the area under the curve (AUC) for both hyperglycemia and hypoglycemia, 24h mean blood glucose (24h MBG), 24h standard deviation of blood glucose (24h SDBG), 24h mean amplitude of glycemic excursion (24h MAGE), PT (percentage of time), and time in range (TIR), were calculated and compared between Basalin group and Lantus group. "
4.	Peripheral Nervous System Diseases (PNS Diseases) 12/01/2017 - "Investigation on effect of basalin coated silver nanoparticles as antioxidant for alleviating peripheral neuropathy in mice treated with oxaliplatin."
5.	Paralysis (Palsy) 01/01/2019 - "Here, we show that the trypanosome TZ protein 'basalin' is essential for building the basal plate, and its loss is associated with CP nucleation defects, inefficient recruitment of CP assembly factors to the TZ, and flagellum paralysis. "

Related Drugs and Biologics

1.	Insulin Glargine (Lantus)
2.	Biosimilar Pharmaceuticals
3.	Glucose (Dextrose)
4.	Silver
5.	Proteins (Proteins, Gene)
6.	Hypoglycemic Agents (Hypoglycemics)
7.	Herbicides
8.	Blood Glucose (Blood Sugar)
9.	Antioxidants
10.	Oxaliplatin (Eloxatin)

Related Therapies and Procedures

1.	Glycemic Control